StockData
BioCryst Pharmaceuticals Inc logo

BioCryst Pharmaceuticals Inc (BCRX) stock

BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$7.30−0.20 (-2.67%)

Close on Nov 18, 2026Market cap $1.87BP/E –Yield –

BioCryst Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

BioCryst Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$313.16M, down 677.8% year over year. For fiscal 2025 it was $340.99M. The highest annual figure on record is $340.99M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$340.99M–
FY2024Dec 31, 2024-$2.54M–
FY2023Dec 31, 2023-$103.71M–
FY2022Dec 31, 2022-$148.44M–
FY2021Dec 31, 2021-$177.72M–
FY2020Dec 31, 2020-$174.76M–
FY2019Dec 31, 2019-$99.46M–
FY2018Dec 31, 2018-$94.22M–
FY2017Dec 31, 2017-$57.41M–
FY2016Dec 31, 2016-$48.61M–
FY2015Dec 31, 2015-$39.44M–
FY2014Dec 31, 2014-$45.77M–
FY2013Dec 31, 2013-$30.72M–
FY2012Dec 31, 2012-$33.89M–
FY2011Dec 31, 2011-$49.59M–
FY2010Dec 31, 2010-$34.36M–
FY2009Dec 31, 2009-$13.74M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$98.47M+230.6%
Q1 FY2026Mar 31, 2026-$701.60M-3405.2%
Q4 FY2025Dec 31, 2025$260.39M–
Q3 FY2025Sep 30, 2025$29.59M+284.7%
Q2 FY2025Jun 30, 2025$29.79M+240.0%
Q1 FY2025Mar 31, 2025$21.23M–
Q4 FY2024Dec 31, 2024-$4.51M–
Q3 FY2024Sep 30, 2024$7.69M–
Q2 FY2024Jun 30, 2024$8.76M–
Q1 FY2024Mar 31, 2024-$14.49M–
Q4 FY2023Dec 31, 2023-$42.67M–
Q3 FY2023Sep 30, 2023-$11.92M–
Q2 FY2023Jun 30, 2023-$20.70M–
Q1 FY2023Mar 31, 2023-$28.42M–
Q4 FY2022Dec 31, 2022-$46.31M–
Q3 FY2022Sep 30, 2022-$17.45M–
Q2 FY2022Jun 30, 2022-$34.72M–
Q1 FY2022Mar 31, 2022-$49.96M–
Q4 FY2021Dec 31, 2021-$52.18M–
Q3 FY2021Sep 30, 2021-$44.58M–
Q2 FY2021Jun 30, 2021-$29.58M–
Q1 FY2021Mar 31, 2021-$51.38M–
Q4 FY2020Dec 31, 2020-$52.41M–
Q3 FY2020Sep 30, 2020-$42.86M–
Q2 FY2020Jun 30, 2020-$38.51M–
Q1 FY2020Mar 31, 2020-$40.98M–
Q4 FY2019Dec 31, 2019-$109.00K–
Q3 FY2019Sep 30, 2019-$35.10M–
Q2 FY2019Jun 30, 2019-$34.92M–
Q1 FY2019Mar 31, 2019-$29.33M–
Q4 FY2018Dec 31, 2018-$25.26M–
Q3 FY2018Sep 30, 2018-$28.49M–
Q2 FY2018Jun 30, 2018-$18.25M–
Q1 FY2018Mar 31, 2018-$22.21M–
Q4 FY2017Dec 31, 2017-$17.86M–
Q3 FY2017Sep 30, 2017-$13.35M–
Q2 FY2017Jun 30, 2017-$15.52M–
Q1 FY2017Mar 31, 2017-$10.69M–
Q4 FY2016Dec 31, 2016-$8.19M–
Q3 FY2016Sep 30, 2016-$9.24M–

More BioCryst Pharmaceuticals figures

See a number that looks wrong?